title: The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
abstract: OBJECTIVE
  The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown.
  
  
  METHODS
  Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks.
  
  
  RESULTS
  In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3 infection). Two of the five initially HBV-DNA positive patients with follow-up available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA became detectable after the clearance of HCV in four initially HBV-DNA negative patients.
  
  
  CONCLUSIONS
  Combination therapy with PEG-IFN-a2b and ribavirin is highly effective in inducing a virological response concerning HCV in patients with HBV/HCV co-infection. However, HBV replication may increase after the clearance of HCV and thus close monitoring for both the viruses is recommended even in patients with initially undetectable HBV-DNA.
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.
authors.forename: Andrej
authors.initials: A
authors.lastname: Potthoff
authors.forename: Heiner
authors.initials: H
authors.lastname: Wedemeyer
authors.forename: Wulf O
authors.initials: WO
authors.lastname: Boecher
authors.forename: Thomas
authors.initials: T
authors.lastname: Berg
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Joachim
authors.initials: J
authors.lastname: Arnold
authors.forename: Ulrich
authors.initials: U
authors.lastname: Spengler
authors.forename: Kurt
authors.initials: K
authors.lastname: Gruengreiff
authors.forename: Thomas
authors.initials: T
authors.lastname: Kaeser
authors.forename: Marcus
authors.initials: M
authors.lastname: Schuchmann
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bergk
authors.forename: Nicole
authors.initials: N
authors.lastname: Forestier
authors.forename: Katja
authors.initials: K
authors.lastname: Deterding
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
authors.forename: Christian
authors.initials: C
authors.lastname: Trautwein
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004279:DNA, Viral / Q000097:blood; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b